About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Florida | 10,975 Studies Near You | Clareo Health

Clinical Trials LocationsFlorida

Clinical Trials in Florida

Discover 10,975 clinical trials near Florida. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 10781-10800 of 10,975 trials

COMPLETEDNA49 miles

D2-EPG Study: Evaluation of New Sensing Circuitry and Capture Management

NCT00328705

This is an acute, prospective, multi-center, non-randomized, investigational device exemption (IDE) clinical study.

Medtronic Cardiac Rhythm and Heart Failure65 participantsStarted May 2006

Tampa, Florida, United States • Coon Rapids, Minnesota, United States • Rochester, Minnesota, United States +2 more locations

COMPLETEDPhase 249 miles

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

NCT00063713

The purpose of this study is to find out whether treatment with VELCADE will increase the time it takes for lymphoma to get worse.

Mantle Cell Lymphoma

Millennium Pharmaceuticals, Inc.152 participantsStarted Jun 2003

Birmingham, Alabama, United States • Berkeley, California, United States • Duarte, California, United States +32 more locations

Find Trials by Condition in Florida

Breast Cancerin Florida Lung Cancerin Florida Prostate Cancerin Florida Colorectal Cancerin Florida Melanomain Florida Leukemiain Florida Lymphomain Florida Pancreatic Cancerin Florida Ovarian Cancerin Florida Brain Cancerin Florida Diabetes

Data from ClinicalTrials.govTerms

COMPLETEDPhase 1/249 miles

YSPSL for Prevention of Delayed Graft Function Part B

NCT00298168

Selectins have been implicated in the pathogenesis of ischemia/reperfusion (I/R)-induced kidney injury and resultant delayed graft function (DGF). PSGL-1 is a ligand for P-, E-, and L-selectin. It has been reported that YSPSL (rPSGL-Ig) blocks P-selectin and, to a lesser degree, E- and L-selectin. Both sPSGL-1 and YSPSL (rPSGL-Ig) have been shown in animal models to reduce both cytokines and tissue damage associated with ischemia reperfusion and to improve renal function post-transplant. Therefore, the current phase I/II clinical study is designed to assess the safety and efficacy of YSPSL (rPSGL-Ig) in preventing DGF in patients undergoing cadaveric kidney transplants and to determine a dose for future pivotal studies.

Kidney Diseases

Y's Therapeutics, Inc.60 participantsStarted May 2006

Los Angeles, California, United States • San Francisco, California, United States • Denver, Colorado, United States +12 more locations

COMPLETEDPhase 449 miles

Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder

NCT00366002

This study will evaluate safety, efficacy and patient's perception of outcome after treatment with darifenacin (7.5 mg once daily (o.d.) with voluntary increase up to 15 mg o.d.) in patients with OAB who are dissatisfied with prior oxybutynin extended release (ER) or tolterodine extended release (ER) therapy.

Overactive Bladder (OAB)

Novartis500 participantsStarted Jun 2006

Birmingham, Alabama, United States • Chandler, Arizona, United States • Mesa, Arizona, United States +79 more locations

UNKNOWNPhase 349 miles

To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids

NCT00053560

The purpose of this clinical trial is to study the effects of GL701 on bone mineral density in women with active systemic lupus erythematosus (SLE) who are also receiving treatment with glucocorticoids (e.g., prednisone).

Genelabs Technologies155 participantsStarted Dec 2002

Tucson, Arizona, United States • Los Angeles, California, United States • North Hollywood, California, United States +23 more locations

COMPLETEDPhase 249 miles

PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease

NCT00525954

The study will be conducted at up to 25 U.S. centers and will be a double-blind randomized parallel group placebo controlled study among subjects with stable coronary artery disease (CAD). Subjects will be randomized to receive either placebo tablets or one of 2 orally active doses of A-002. The duration of study drug therapy will be 8 weeks.

Coronary Artery Disease

Anthera Pharmaceuticals120 participantsStarted Sep 2007

Mobile, Alabama, United States • Scottsdale, Arizona, United States • Hudson, Florida, United States +10 more locations

COMPLETEDPhase 349 miles

Study of Rebamipide Eye Drops to Treat Dry Eye

NCT00201981

The purpose of this study is to determine the potential safety and effectiveness of rebamipide eye drops, an investigational eye drop being developed for the treatment of keratoconjunctivitis sicca (dry eye).

Keratoconjunctivitis Sicca

Otsuka Pharmaceutical Development & Commercialization, Inc.740 participantsStarted May 2004

Birmingham, Alabama, United States • Glendale, Arizona, United States • Peoria, Arizona, United States +60 more locations

WITHDRAWNPhase 349 miles

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

NCT00226668

The purpose of this study is to examine the safety and efficacy of XERECEPT (human Corticotropin-Releasing Factor, or hCRF) compared to dexamethasone in patients with primary malignant glioma who require increased dexamethasone doses to control symptom of peritumoral brain edema.

Brain EdemaBrain Tumor

Celtic Pharma Development Services120 participantsStarted Jan 2006

Phoenix, Arizona, United States • La Jolla, California, United States • Newport Beach, California, United States +23 more locations

COMPLETEDPhase 457 miles

Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder

NCT00127270

This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.

Urinary Incontinence

Novartis395 participantsStarted May 2005

Birmingham, Alabama, United States • Tucson, Arizona, United States • Culver City, California, United States +64 more locations

COMPLETEDPhase 357 miles

A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder

NCT00106860

The purpose of the study is to assess the safety and effectiveness of the experimental drug, a benzodiazepine drug, in long-term use and the effects on quality of life, social and occupational functioning, sleep, and daytime sedation in subjects with anxiety disorder.

Anxiety Disorder

Jazz Pharmaceuticals158 participantsStarted Mar 2005

Bradenton, Florida, United States • Jacksonville, Florida, United States • St. Petersburg, Florida, United States +10 more locations

COMPLETEDPhase 260 miles

Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).

NCT00159627

The purpose of this study is to evaluate the safety of KW-3902IV compared to placebo and to determine the diuretic effect of KW-3902IV compared to placebo in patients hospitalized with volume overload due to CHF who are refractory to high dose diuretic therapy.

Heart Failure, Congestive

NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)52 participantsStarted Aug 2004

Stanford, California, United States • Washington D.C., District of Columbia, United States • Sarasota, Florida, United States +7 more locations

COMPLETEDPhase 261 miles

Efficacy Study of EVT 201 in the Treatment of Elderly Patients With Daytime Sleepiness

NCT00401284

The purpose of this study is to determine whether a compound known as EVT 201 is effective in treating elderly patients diagnosed with primary insomnia who also have moderate daytime sleepiness.

Sleep Initiation and Maintenance Disorders

Evotec Neurosciences GmbH135 participantsStarted Nov 2006

Phoenix, Arizona, United States • Tucson, Arizona, United States • Los Angeles, California, United States +19 more locations

COMPLETEDPhase 288 miles

Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients

NCT00046371

The purpose of this study is to examine the immunological response rate to administration of the THERATOPE® vaccine in women with stable metastatic breast cancer who are being treated with aromatase inhibitors or Faslodex® and who do not require chemotherapy. Post-menopausal women on aromatase inhibitors or Faslodex® alone and pre-menopausal women on aromatase inhibitors plus luteinising hormone-releasing hormone (LH/RH)-agonist may be eligible to be enrolled. Patients must not have had radiotherapy or major surgery within four (4) weeks prior to entering the study. Information about the safety and tolerability of administration of the THERATOPE® vaccine will also be gathered during the course of the study.

Breast Neoplasms

Oncothyreon Canada Inc.Started Aug 2002

Berkeley, California, United States • San Francisco, California, United States • Santa Monica, California, United States +14 more locations

COMPLETEDPhase 4113 miles

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects

NCT00413790

This study will evaluate the pharmacologic effects of exposure to darifenacin and tolterodine on cardiovascular parameters in healthy subjects 50 years of age and older

Novartis162 participantsStarted Nov 2006

Scottsdale, Arizona, United States • Tempe, Arizona, United States • San Diego, California, United States +9 more locations

COMPLETEDPhase 3131 miles

Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

NCT00171483

Study to assess the effects of tegaserod added to PPI therapy in the resolution of heartburn and regurgitation in patients with incomplete relief from PPIs .

Gastroesophageal Reflux Disease (GERD)

Novartis30 participantsStarted Jan 2004

Boynton Beach, Florida, United States • Miami, Florida, United States • Pembroke Pines, Florida, United States +4 more locations

COMPLETEDPhase 2136 miles

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

NCT00051974

The purpose of this study is to evaluate how tumors in patients with non-small cell lung cancer respond to treatment with VELCADE alone versus VELCADE given with docetaxel and also to see what effects (good and bad) it has on you and your cancer.

Non-Small Cell Lung Cancer

Millennium Pharmaceuticals, Inc.155 participantsStarted Dec 2002

Birmingham, Alabama, United States • Los Angeles, California, United States • Los Angeles, California, United States +17 more locations

COMPLETEDPhase 1/2161 miles

Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma

NCT00056173

This phase II, 43 patient trial, will evaluate the efficacy of GTI-2040, an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase (RNR) mRNA, in combination with capecitabine, in the setting of advanced/metastatic renal cell carcinoma. Preclinical studies have shown synergy between GTI-2040 and capecitabine against renal cell carcinoma.

Carcinoma, Renal CellMetastases, Neoplasm

Aptose Biosciences Inc.43 participantsStarted Mar 2002

Concord, California, United States • Los Angeles, California, United States • Torrance, California, United States +7 more locations

COMPLETEDPhase 4166 miles

Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age

NCT00192140

* To describe the proportion of individuals 5-49 years of age who shed vaccine strain viruses. * To describe the duration of shedding of vaccine viruses in individuals 5-49 years of age. * To describe the genotypic and phenotypic stability of shed vaccine viruses. * To describe the immune responses of FluMist in individuals 5-49 years of age. * To describe the safety of FluMist in individuals 5-49 years of age in relation to shedding and the immune response

MedImmune LLC345 participantsStarted Jun 2004

Miami, Florida, United States • Chicago, Illinois, United States • Bardstown, Kentucky, United States +8 more locations

COMPLETEDPhase 4166 miles

Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis

NCT00121381

Atopic dermatitis, also called eczema, is characterized by redness, papulation (skin elevation) and pruritus (skin itching). The active ingredient of pimecrolimus inhibits the T-cell activation. These cells are involved in the inflammatory component of the disease. This study will test the safety of pimecrolimus Cream 1% with topical corticosteroid treatment (commonly used in eczema) in patients with severe atopic dermatitis.

Dermatitis, Atopic

Novartis400 participantsStarted May 2005

Huntington Beach, California, United States • San Diego, California, United States • Denver, Colorado, United States +10 more locations

COMPLETEDPhase 3518 miles

Carotid Artery Revascularization Using the Boston Scientific EPI Filter Wire EZ™ and the EndoTex™ NexStent™

NCT00600327

The primary objective of this study is to demonstrate the safety of the NexStent for treatment of carotid artery lesions undergoing stenting with adjunctive use of the FilterWire distal embolic protection device. The rates will be compared to an Objective Performance Criterion (OPC) derived from historic data from high-risk patients undergoing surgical intervention with Carotid endarterectomy. Patients included in this study are those at higher risk for complications associated with CEA.

Transient Ischemic AttackThromboembolic StrokeStroke Prevention

Boston Scientific Corporation488 participantsStarted Dec 2001

Phoenix, Arizona, United States • Mountain View, California, United States • Newport Beach, California, United States +16 more locations

PreviousPage 540 of 549Next

in Florida

Heart Diseasein Florida